Explore it now
27th Annual ESGO 2026 Congress
Discover it Now!
ENGOT coordinates and promotes gynaecological cancer clinical trials in Europe
Explore ENGOT
Explore ESGO’s Membership Benefits
Read More
The assesment is based on European Training Requirements for Gynaecological Oncology (ETR).
Click here to download.
Kickstart your preparation for the ESGO Exam with the ESGO Textbook in Gynaecological Oncology and the ESGO Gynecologic Oncology Portal - eAcademy. Please note these are not complete and/or exhaustive sources and refer to recommended readings for the full list of sources.
Questions will contain organ specific questions:
As well as generic modules:
Which of the following is the most frequent symptom among gynaecological cancer patients throughout their treatment leading to palliative care referral?
PARP inhibitor therapy is an option in platinum-sensitive high-grade serous ovarian cancer relapse. Which statement is accurate?
Which of the following is a common feature of high-grade serous ovarian carcinoma on histopathology?
What is the purpose of sonohysterography according to the IETA consensus?
A 60-year-old patient is referred because of recurrent endometrial cancer (endometrioid grade 3, pMMR). The initial treatment included hysterectomy, bilateral salpingo-oophorectomy, and sentinel lymph node biopsy, followed by adjuvant chemotherapy and external beam radiotherapy. After two years of follow-up, the patient has multiple lung and liver metastases on PET-CT and mild symptoms of recurrence. What is the optimal treatment?
According to the revised FIGO 2021 classification for vulvar cancer, which of the following is correct?
In anterior exenterative surgery…
Which measure of association is typically used in cohort studies to compare the risk of disease between exposed and unexposed groups?
What are the strongest prognostic factors in vaginal cancer, besides disease stage?
A 32-year-old woman presents with irregular vaginal bleeding and persistent elevated β-hCG levels following a miscarriage. A pelvic ultrasound shows a heterogenous mass in the uterus. Histopathology after curettage confirms a diagnosis of choriocarcinoma. What is the most common site of metastasis for choriocarcinoma?
18.12.2025 - 16.1.2026 Madrid, Spain Level: Advanced
Learn more
14.12.2026 - 15.12.2026 Milan, Italy Level: Advanced